Brief: Tenaya Therapeutics Presents Encouraging New Data For The Potential Treatment Of Heart Failure
09/10/2023 13:40
Oct 9 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS PRESENTS ENCOURAGING NEW CLINICAL AND
PRECLINICAL DATA FROM HDAC6 INHIBITOR PROGRAM TN-301 FOR THE
POTENTIAL TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION
FRACTION AT THE 2023 HFSA ANNUAL SCIENTIFIC MEETING
Source text for Eikon: ID:nGNX9WJK2K
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027